- Anavex Life Sciences (AVXL +4.8%) is up on almost 50% higher volume in reaction to the results from a study evaluating the gut microbiota of Alzheimer's patients enrolled in its Phase 2a extension study of ANAVEX 2-73.
- The analysis showed that patients receiving ANAVEX 2-73, a sigma-1 receptor (S1R) agonist, had high levels of two gut microbiota families that were associated with improved daily living activities at week 148.
- CEO Christopher Missling, Ph.D. says, “This is the first gut microbiota DNA sequencing analysis of Alzheimer’s disease patients treated with ANAVEX 2-73 which might help to identify potential biomarkers of response for ANAVEX 2-73. We continue to advance the ANAVEX 2-73 Alzheimer’s disease program through the ongoing Phase 2b/3 Alzheimer’s disease clinical study and in other ongoing ANAVEX 2-73 clinical trials focused on serious neurology diseases with high unmet needs, including Rett syndrome and Parkinson’s disease dementia.”